First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
ANN ARBOR, Mich., May 20, 2024 Esperion and Otsuka Pharmaceutical Co., Ltd announced today that the primary endpoint was achieved in the Phase 3 trial in Japan for bempedoic acid as a.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.